Halozyme abandons its €2bn pursuit of Evotec

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations

BMS upgrades Evotec neurology alliance, now worth up to $4bn

Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod

Boehringer takes on antimicrobial resistance with Evotec, bi...

A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections.

BMS pays $200m to expand Evotec alliance on protein degrader...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation.

Vifor joins forces with Evotec on kidney disease joint ventu...

Evotec announces potential $850m R&D partnership with Takeda

Germany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, focusing on discovering small molecule drugs